Systematic reviews and meta-analyses

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 5, 2011, Pages 582-593

  Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Meta analysis; Operational research; Systematic review; Tuberculosis research

Indexed keywords

ACCESS TO INFORMATION; DATA ANALYSIS; DATA BASE; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METHODOLOGY; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RESEARCH SUBJECT; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMATIC REVIEW (TOPIC);

GUIDELINES AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; POLICY MAKING; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC;

EID: 79954549212     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0719     Document Type: Review

References (69)

1. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 2007; 7: e1000326.
2. Schunemann H J, Fretheim A, Oxman A D, WHO Advisory Committee on Health Research. Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst 2006; 4: 13.
3. Oxman A D, Schunemann H J, Fretheim A. Improving the use of research evidence in guideline development. 14: Reporting guidelines. Health Res Policy Syst 2006; 4: 26.
4. Cochrane handbook for systematic reviews of intervention. Version 5.01. Chichester, UK: The Cochrane Colaboration: 2008.
5. Oxman A D, Schunemann H J, Fretheim A. Improving the use of research evidence in guideline development. 2: Priority setting. Health Res Policy Syst 2006; 4: 14.
6. Schunemann H J, Oxman A D, Fretheim A. Improving use of research evidence in guideline development. 6: Determining which outcomes are important. Health Res Policy Syst 2006; 4: 18.
7. Richardson W S, Wilson M C, Nisbikawa J, Hayward R S A. The well-built clinical question: a key to evidence-based decisions. ACP Journal Club 1995; A12-A13.
8. Oxman A D, Schunemann H J, Fretheim A. Improving the use of research evidence in guideline development. 8: Synthesis and presentation of evidence. Health Res Policy Syst 2006; 1: 19.
9. Golder S, Loke Y K. Search strategies to identify information on adverse effects: a systematic review. J Med Libr Assoc 2004; 97: 84-85.
10. Center for Reviews and Dissemination. Finding studies for systematic reviews: a checklist for researchers. York, UK: University of York, 2006.
11. Moher D, Pham B, Klassen T P, et al. What contributions do languages other than English make on the results of meta-analysis? J Clin Epidemiol 2000; 53: 964-972.
12. Ramos J M, Padilla S, Masia M, Gutierrez F. A bibliometric analysis of tuberculosis research indexed in PubMed, 1997-2006. In J Tuberc Lung Dis 2008; 12: 1461-1467.
13. McArthur L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000; 356: 1228-1231.
14. Canadian Agency for Drugs and Technologies in Health. Grey matters: a practical search tool for evidence-based medicine. Ottawa, ON, Canada: Information Services, CADTH, 2009.
15. Mother D, Jadad A R, Nichol G, Pernman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: annotated bibliography of scales and checklists. Control Clin Trials 1995; 16: 62-73.
16. Sanderson S, Tatt I D, Higgins J P. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36: 666-676. (Pubitemid 47244573)
17. Verhagen A P, De Vet H C W, de Bie R A, et al. The Delphi list; a criteria list for quality assessment of randomized clinical trials for conducting reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-1241. (Pubitemid 29009523)
18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of randomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605.
19. von Elm E, Altman D G, Egger M, Pocock S, Gotzsche P C, Vandenbroucke J P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.
20. Whiting P, Rutjes A W, Reitsma J B, Bossuyt P M, Kleijnen J. The development of QUADAS: a tool for quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
21. Whiting P F, Weswood M E, Rutjes A W, Reitsma J B, Bossuyt P N, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9.
22. Shea B J, Grimshar J M, Wells G A, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10.
23. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36).
24. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis? Lancet 1998; 352: 609-613.
25. Bhogal S K, Teasell R W, Foley N C, Speechley M R. The PEDro scale provides a more comprehensive measure of methodological quality than the Jadad scale in the stroke rehabilitation literature. J Clin Epidemiol 2005; 58: 668-673. (Pubitemid 40797896)
26. Moher D, Hopewell S, Schulz K F, et al. CONSORT 2010 explanation and elaboration: update guidelines for reporting parallel group randomized trials. BMJ 2010; 340: c869.
27. Wangge G, Klungel O H, Roes K C B, de Boer A, Hoes M O, Knol M J. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS Med 2010; 5: e13550.
28. Bossuyt P M, Reitsma J B, Bruns D E, et al. Towards complete and accurate reporting studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003; 138: 40-44. (Pubitemid 36232093)
29. Bossuyt P M, Reitsma J B, Bruns D E, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-W12.
30. Cattamanchi A, Smith R, Steingart K, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and metaanalysis. J Acquir Immune Defic Syndr 2011; 56: 230-238.
31. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 12-134.
32. Ling D I, Zwerling A A, Pai M. Genotype MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: meta-analysis. Eur Respir J 2008; 32: 1165-1174.
33. Bang D, Bengard Andersen A, Thomsen V O. Rapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J Clin Microbiol 2006; 44: 2605-2608.
34. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792. (Pubitemid 351490566)
35. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43: 3699-3703. (Pubitemid 41129648)
36. Hillemann D, Rusch-Gerdes S, Richter E. Application of the Genotype MTBDR assay directly on sputum specimens. Int J Tuberc Lung Dis 2006; 10: 1057-1059. (Pubitemid 44378986)
37. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640.
38. Makinen J, Marttila H J, Marjamaki M, Viljanen M K, Soini H. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 350-352. (Pubitemid 43222221)
39. Miotto P, Piana F, Penati V, Canducci F, Migliori G B, Cirillo D M. Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol 2006; 44: 2485-2491.
40. Miotto P, Piana F, Cirillo D M, Migliori G B. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2008; 46: 393-394.
41. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M. Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the M ycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 2006; 44: 4459-4463.
42. Cohn D L, Catlin B J, Peterson K L, Judson F N, Sbarbaro J A. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twiceweekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112: 407-415.
43. Seung K J, Gelmanova I E, Peremitin G G, Golubchikova V T, Pavlova V E, Sirotkina O B, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004; 39: 1321-1328. (Pubitemid 39458518)
44. Controlled clinical trial of four short-course regimens of c hemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. Third East African/British Medical Research Council Study. Am Rev Respir Dis 1978; 118: 39-48.
45. Controlled clinical trial of four short-course regimens of chemo therapy for two durations in the treatment of pulmonary tuberculosis: second report. Third East African/British Medical Research Council Study. Tubercle 1980; 61: 59-69.
46. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: first report. Am Rev Respir Dis 1978; 118: 219-228.
47. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 1979; 60: 201-210.
48. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 579-585.
49. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981; 62: 95-102.
50. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1986; 133: 779-783.
51. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; 1: 171-174.
52. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council. Tubercle 1982; 63: 89-98.
53. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987; 136: 1339-1342.
54. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 1983; 64: 153-166.
55. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 1986; 67: 5-15.
56. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study. Am Rev Respir Dis 1985; 131: 727-731.
57. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1989; 139: 871-876.
58. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1985; 132: 374-378.
59. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1988; 137: 1147-1150.
60. Zierski M, Bek E, Long M W, Snider D E Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 1980; 122: 879-889. (Pubitemid 11207865)
61. Zierski M, Bek E, Long M W, Snider D E Jr. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis 1981; 124: 249-251. (Pubitemid 11003986)
62. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service/T uberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1991; 143: 262-267.
63. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study. Am Rev Respir Dis 1989; 140: 990-995.
64. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, threetimes-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1991; 143: 700-706.
65. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1991; 143: 707-712.
66. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. Am Rev Respir Dis 1986; 134: 27-33.
67. Balasubramanian R, Sivasubramanian S, Vijayan V K, Ramachandran R, Jawahar M S, Paramasivan C N, et al. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India. Tubercle 1990; 71: 253-258.
68. Santha T, Rehman F, Mitchison D A, Sarma G R, Reetha A M, Prabhaker R, Tuberculosis Research Centre, Indian Council of Medical Research. Splitdrug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis - a unique approach. Trop Med Int Health 2004; 9: 551-558.
69. Moher D, Liberti A, Tetzlaff J, Altman D G, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.